In the US there are more new starts on Keytruda than any other immunotherapy, Merck says in first-quarter earnings report.
Merck & Co. Inc.'s PD-1 inhibitor Keytruda came very close to matching Bristol-Myers Squibb Co.'s competing Opdivo in the first quarter, with $1.46bn and $1.51bn in sales, respectively – but while the immuno-oncology news is great, investors are still clamoring for growth in other areas.
Keytruda sales were up by 151%, the firm reported May 1, while Opdivo had risen 34% from the same period...
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
